Received Feb 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | LA |
Rash was reported as worsened; This non-serious case was reported by a consumer via sales rep and described the occurrence of rash in a 51-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of injection site pain (received a 1st dose on 21st October 2024 in left arm and had Injection site pain, refer case US2024131039). On 21-JAN-2025, the patient received the 2nd dose of Shingrix (left deltoid). On 23-JAN-2025, 2 days after receiving Shingrix, the patient experienced rash (Verbatim: Rash was reported as worsened). The outcome of the rash was not resolved. The reporter considered the rash to be related to Shingrix. The company considered the rash to be related to Shingrix. Linked case(s) involving the same patient: US2024131039 Additional Information: GSK Receipt Date: 23-JAN-2025 Patient was the reporter. Rash was reported as worsened. Patient received a subsequent dose of vaccine. For tolerance to 1st dose, refer case US2024131039.; Sender's Comments: US-GSK-US2024131039:Same patient